Medical Cannabis Studies

A

• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)

B

• batten-disease (6)

• benefits (9)

• breast-cancer (7)

C

• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)

D

• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)

E

• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)

F

• fibromyalgia (2)

• fibrosis (1)

G

• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)

H

• health-care (1)

• hiv (7)

• huntingtons-disease (1)

I

• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)

K

• krabbe-disease (4)

L

• liver (2)

• lung-cancer (2)

• lupus (1)

M

• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)

N

• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)

P

• pain (29)

• pancreatitis (1)

• prostate-cancer (2)

S

• schizophrenia (2)

• skin (1)

• sports (3)

T

• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid (2008)

    Cannabidiol has the ability to kill glioma cells both in vitro and in vivo, independently of the stimulation of cannabinoid receptors. In this study performed in mice, the in vivo exposure of the tumor tissues with cannabidiol demonstrated a significant decrease in the activity and content of 5-lipoxygenase (LOX, 40%) and its final pipeline, leukotriene B4 (25 %). It is demonstrated in this study that cannabidiol exerts its antitumor effects through the modulation of the LOX pathway and the endocannabinoid system. This suggests a possible interaction of these routes in the control of tumor growth. View study

  • 9-Tetrahydrocannabinolic acid synthase production in Pichia pastoris enables chemical synthesis of cannabinoids (Page not found)

    View study

  • A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells (2006)

    Cannabidiol hydroxyquinone (HU-331) has a great potential to become an antiangiogenic and anticancer drug. This study demonstrated that HU-331 was able to significantly inhibit angiogenesis at very low concentrations, in addition to significantly decreasing the total area occupied by the vessels in the treated tumors. View study

  • A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma (2011)

    Gliobastoma multiforme is highly resistant to current cancer treatments. However, the combined administration of D9 tetrahydrocannabinol and temozolomide exerts a strong antitumor action on glioma xenografts, suggesting that it could be exploited therapeutically for the treatment of gliobastoma multiforme. View study

  • A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology (2008)

    THC competitively inhibits the enzyme acetylcholinesterase (AChE) and prevents the aggregation of amyloid ? peptide induced by AChE (A?), the key pathological marker of Alzheimer’s disease. View study

  • A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes. (2018)

    In Canada, the Cannabis Access Regulation for Medical Purposes (ACMPR) has granted practicing nurses (NPs) the power to authorize cannabis for therapeutic purposes (CTP) to eligible patients. This national study was focused to assess NPs�knowledge and practice gaps related to CTP to inform the development of future education resources that increase NPs’ clinical competence and improve patient care related to medical cannabis. View study

  • A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers (2013)

    The objective of this study was to evaluate the possible drug interactions of the oromucosal aerosol of THC and CBD Sativex�, nabiximols in combination with the cytochrome P450 (CYP450) inducer (rifampin) or inhibitors (ketoconazole or omeprazole). Based on our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes in the PK parameters of the THC / CBD spray, but potential effects should be considered when co-administered THC / CBD with compounds that share the CYP3A4 pathway like rifampicin or ketoconazole. View study

  • A pilot clinical study of ?9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme (2006)

    Due to its ability to inhibit tumor growth in animals, THC and other cannabinoids have been suggested as antitumor drugs. This is the first clinical study to test the application of THC in human patients with recurrent glioblastoma multiforme. The results demonstrate the safety profile of THC and its action on tumor cells, which establishes the basis for future trials. View study

  • A prospective observational study of problematic oral cannabinoid use. (2017)

    The present study focused on two objectives. The first objective of this study was to examine the incidence of problematic use of prescription cannabinoids (PPCBU) over a period of 12 months among patients who started treatment with cannabinoids. The second objective was to examine the factors associated with PPCBU. View study

  • A Review of Molecular Pharmacology (2001)

    In this review the effects of THC and gamma-linolenic acid (GLA, in hemp seed oil) on the metabolism of eicosanoids are analyzed and THC is proposed to act as a selective inhibitor of cyclooxygenase-2 (COX) -2). View study

  • A selective review of medical cannabis in cancer pain managment. (2017)

    Insufficient management of chronic and neuropathic pain associated with cancer adversely affects the patient’s quality of life. The objective of this review was to present a selection of representative clinical studies, which evaluated the efficacy of cannabinoid-based treatments containing tetrahydrocannabinol (THC) and cannabidiol (CBD) to reduce pain associated with cancer. View study

  • A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol (2006)

    The combination of tetrahydrocannabinol and cannabidiol increases clinical efficacy in the treatment of spasticity, central pain, lower urinary tract symptoms in multiple sclerosis, sleep disorders, peripheral neuropathic pain, avulsion symptoms of the branchial plexus, arthritis rheumatoid pain and intractable cancer, in addition to reducing the occurrence of adverse effects. View study

  • Action of Cannabidiol on the Anxiety and Other Effects Produced by D9-THC in Normal Subjects (1982)

    It was verified that cannabidiol blocks anxiety caused by D9-tetrahydrocannabinol, in addition to blocking other effects similar to those of marijuana. The results of this study suggest that the effects of cannabidiol, unlike the effects of D9-tetrahydrocannabinol, could be involved in the antagonism of the effects between the two cannabinoids. View study

  • Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus (2006)

    Cannabinoids have anticonvulsant properties, but their effects have not been evaluated in hippocampal neuronal culture models of acquired epilepsy (AD) and status epilepticus (SE). The results of this study represent powerful tools to investigate the molecular mechanisms that mediate the effects of cannabinoids on neuronal excitability. View study

  • Activation of Type 1 Cannabinoid Receptor (CB1R) Promotes Neurogenesis in Murine Subventricular Zone Cell Cultures (2013)

    These results demonstrate that the activation of the endocannabinoid receptor CB1R induces the proliferation, self-renewal and neuronal differentiation of the cell cultures of the neonatal subventricular zone in animal models. View study

  • Activity of cannabis in relation to its delta'-trans-tetrahydro-cannabinol content (1981)

    Tetrahydrocannabinol (THC) can represent about one third of the activity of the herb or cannabis resin. In this study it has been shown that some fractions of the crude drug show an inhibitory effect, while others have a THC enhancing effect, which can have an important influence on the types of cannabis preparation used. View study

  • Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease (2016)

    The positive regulation of the galaninnergic and endocannabinoid systems supports the hypothesis of their neuroprotective functions, which are established before clear clinical cognitive symptoms of Alzheimer’s disease appear. View study

  • Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion (2010)

    This is the first study to demonstrate an antiarrhythmic effect of cannabidiol (CBD) after myocardial ischemia and reperfusion (I / R), and it is also the first to demonstrate that acute administration of a single dose of CBD is sufficient to reduce myocardial tissue injury, regardless of whether it is administered before or after coronary occlusion. Although more detailed studies are required to elucidate the mechanism by which CBD conserves tissue in I / R, this data extends to the currently very limited literature that details the role of CBD in the cardiovascular system and firmly establishes its potential as an cardioprotective agent. View study

  • Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats (2009)

    THC acts as a homeostatic modifier that worsens the reward effects of morphine in naive animal models, but which would improve deficits in maternal models. This suggests the use of cannabis individuals subjected to an adverse postnatal environment. View study

  • Agonistic Properties of Cannabidiol at 5-HT1a Receptors (2005)

    This study demonstrates that cannabidiol (CBD) is a modest agonist at the human 5-HT1a receptor. However, additional work and studies are needed to compare the potential of CBD with other serotonin receptors and other species. The results indicate that CBD is potentially useful beyond the domain of cannabinoid receptors. View study

  • Allosteric Modulation of the Cannabinoid CB1 Receptor (2005)

    We investigated the pharmacology of three new compounds, Org 27569, Org 27759, and Org 29647 in the CB1 cannabinoid receptor. In the equilibrium binding assays, the Org compounds significantly increased the binding of a CB1 receptor agonist, indicative of an allosteric effect of positive cooperation. The data presented demonstrate for the first time, that the cannabinoid receptor CB1 contains an allosteric binding site that can be recognized by synthetic small molecule ligands. View study

  • Alterations in the endocannabinoid system in the rat valproic acid model of autism (2013)

    Prenatal exposure to valproic acid is associated with alterations in the endocannabinoid system of the brain. These results indicate that it is possible that endocannabinoid dysfunction may be the basis of behavioral abnormalities observed in autism spectrum disorders. View study

  • Altered striatal reward processing in abstinent dependent cannabis users: Social context matters. (2019)

    The public perception of cannabis as relatively harmless, together with the declared medical benefits, has led to progress towards its legalization. The present study aimed to investigate whether cannabis dependence is associated with lasting alterations in behavioral and neural responses to social reward in 23 abstinent cannabis-dependent men and 24 matched non-using controls. View study

  • American Medical Society for Sports Medicine position statement: concussion in sport. (2013)

    Concussion is defined as a transient alteration of traumatically induced brain function and involves a complex pathophysiological process. The purpose of this article was to provide a summary of best practices based on evidence to help physicians with the evaluation and management of sports concussion. View study